Stock listing

Maxcyte, Inc.

Selected listing: A2AGVE · LS · EUR · DE

Maxcyte, Inc. (Lang & Schwarz: A2AGVE), Health Technology. Latest release Sep 23, 2026: MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development…

A2AGVE:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2AGVE
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Maxcyte, Inc.

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

September 23, 2026

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

August 19, 2026

MaxCyte Reports Second Quarter 2026 Financial Results

August 12, 2026

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

July 21, 2026

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

July 15, 2026

All Maxcyte, Inc. news →

Events

Replays

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call
Wed, Aug 12, 2026 · 04:30 PM ET
Watch
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call
Tue, May 12, 2026 · 04:30 PM ET
Watch
MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call
Tue, Mar 24, 2026 · 04:30 PM ET
Watch

Research Maxcyte, Inc.

Maxcyte, Inc. company profile

View the public company page for Maxcyte, Inc. on 6ix.

Maxcyte, Inc. news

Read company news and market updates connected to Maxcyte, Inc..

Maxcyte, Inc. investor events

Find investor webinars, events, and replay context for Maxcyte, Inc..